A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Advanced esophageal squamous cell cancer (ESCC) is frequently diagnosed in elderly patients. The impact of 2nd line chemotherapy is poorly defined. Recent data demonstrated effectiveness of checkpoint inhibitors in different squamous cell carcinomas. Therefore, we assess combined nivolumab/ipilimumab as 2nd line therapy in elderly ESCC patients. METHODS: RAMONA is a multicenter open-label phase II trial. The primary objective is to demonstrate a significant survival benefit of nivolumab/ipilimumab in advanced ESCC compared to historical data of standard chemotherapy. Primary endpoint is therefore overall survival (OS). Major secondary objective is the evaluation of tolerability. Time to QoL deterioration will thus be determined as key secondary endpoint. Further secondary endpoints are tumor response, PFS and safety. We aim to recruit a total of n = 75 subjects that have to be > 65 years old. Eligibility is determined by the geriatric status (G8 screening and Deficit Accumulation Frailty Index (DAFI)). A safety assessment will be performed after a 3 cycle run-in phase of nivolumab (240 mg Q2W) to justify escalation for eligible patients to combined nivolumab (240 mg Q2W) and ipilimumab (1 mg/kg Q6W), while the other patients will remain on nivolumab only. RAMONA also includes translational research sub-studies to identify predictive biomarkers, including PD-1 and PD-L1 evaluation at different time points, establishment of organoid cultures and microbiome analyses for response prediction. DISCUSSION: The RAMONA trial aims to implement checkpoint inhibitors for elderly patients with advanced ESCC as second line therapy. Novel biomarkers for checkpoint-inhibitor response are analyzed in extensive translational sub-studies. TRIAL REGISTRATION: EudraCT Number: 2017-002056-86 ; NCT03416244 , registered: 31.1.2018.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Combination ICI may also provide benefit over PD-1/PD-L1 blockade alone in ovarian cancer, small cell lung cancer, castration-resistant prostate cancer, esophageal cancer, sarcoma, and glioblastoma20–29.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [26]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
van Hagen, P., Hulshof, M. C. C. M., van Lanschot, J. J. B., Steyerberg, E. W., Henegouwen, M. I. V. B., Wijnhoven, B. P. L., Richel, D. J., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112088 · Cited by 5,521
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Kang, Y.-K., Boku, N., Satoh, T., Ryu, M.-H., Chao, Y., Kato, K., Chung, H. C., Chen, J.-S., Muro, K., Kang, W. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31827-5 · Cited by 2,252
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745
Epidemiology of Esophageal Squamous Cell Carcinoma
Abnet, C. C., Arnold, M., & Wei, W.-Q. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.08.023 · Cited by 1,672
Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244
A review of human carcinogens–Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish
Secretan, B., Straif, K., Baan, R., Grosse, Y., El Ghissassi, F., Bouvard, V., Benbrahim-Tallaa, L., Guha, N., Freeman, C., Galichet, L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70326-2 · Cited by 1,114
Shaverdian, N., Lisberg, A. E., Bornazyan, K., Veruttipong, D., Goldman, J. W., Formenti, S. C., Garon, E. B., & Lee, P. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30380-7 · Cited by 1,091
Hellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., Ready, N. E., Gerber, D. E., Chow, L. Q., Juergens, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30624-6 · Cited by 962
Management of Cancer in the Older Person: A Practical Approach
Balducci, L., & Extermann, M. (2000) · The Oncologist · doi:10.1634/theoncologist.5-3-224 · Cited by 939
Sharabi, A. B., Lim, M., DeWeese, T. L., & Drake, C. G. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00007-8 · Cited by 899
Horn, L., Spigel, D. R., Vokes, E. E., Holgado, E., Ready, N., Steins, M., Poddubskaya, E., Borghaei, H., Felip, E., Paz-Ares, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.3062 · Cited by 861
Chow, L. Q. M., Haddad, R., Gupta, S., Mahipal, A., Mehra, R., Tahara, M., Berger, R., Eder, J. P., Burtness, B., Lee, S.-H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1478 · Cited by 857
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
Drake, C. G., Lipson, E. J., & Brahmer, J. R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.208 · Cited by 422
Morris, V. K., Salem, M. E., Nimeiri, H., Iqbal, S., Singh, P., Ciombor, K., Polite, B., Deming, D., Chan, E., Wade, J. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30104-3 · Cited by 406
Kudo, T., Hamamoto, Y., Kato, K., Ura, T., Kojima, T., Tsushima, T., Hironaka, S., Hara, H., Satoh, T., Iwasa, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30181-x · Cited by 377 · cited 1×
“With respect to esophageal cancer, preliminary results from an Asian study indicate efficacy of nivolumab [9].”
ResultDoi, T., Piha-Paul, S. A., Jalal, S. I., Saraf, S., Lunceford, J., Koshiji, M., & Bennouna, J. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.9846 · Cited by 318
Steevens, J., Schouten, L. J., Goldbohm, R. A., & van den Brandt, P. A. (2010) · Gut · doi:10.1136/gut.2009.191080 · Cited by 265
Chandra, R. A., Wilhite, T. J., Balboni, T. A., Alexander, B. M., Spektor, A., Ott, P. A., Ng, A. K., Hodi, F. S., & Schoenfeld, J. D. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046028 · Cited by 229
Cohen, H. J., Smith, D., Sun, C., Tew, W., Mohile, S. G., Owusu, C., Klepin, H. D., Gross, C. P., Lichtman, S. M., Gajra, A., et al. (2016) · Cancer · doi:10.1002/cncr.30269 · Cited by 203
Kojima, T., Muro, K., Francois, E., Hsu, C.-H., Moriwaki, T., Kim, S.-B., Lee, S.-H., Bennouna, J., Kato, K., Lin, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.2 · Cited by 202
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
Passiglia, F., Bronte, G., Bazan, V., Natoli, C., Rizzo, S., Galvano, A., Listì, A., Cicero, G., Rolfo, C., Santini, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7582 · Cited by 165
Ishiguro, S., Sasazuki, S., Inoue, M., Kurahashi, N., Iwasaki, M., & Tsugane, S. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.10.020 · Cited by 155
Chen, M., Chen, P.-T., Chen, W., Lu, M., Lin, P.-Y., & Lee, K. (2016) · Oncotarget · doi:10.18632/oncotarget.6861 · Cited by 146
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Mössner, R., Ugurel, S., Zimmer, L., Gutzmer, R., & for the “Cutaneous Side Effects” Committee of the Work Group Dermatological Oncology (ADO) (2016) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13047 · Cited by 118 · cited 1×
“, [14, 15] a safety assessment will be performed after 3 cycles of nivolumab monotherapy (6 weeks), during which the investigator will decide if a patient is eligible to receive nivolumab/ipilimumab combination therapy (Nivo 240mg fixed dose Q2W; ipilimumab 1mg/kg Q6W; arm A) or continues nivolumab monotherapy (240 mg…”
BackgroundEsophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy
Thallinger, C., Raderer, M., & Hejna, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.7599 · Cited by 112
Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma
Kähler, K. C., & Hauschild, A. (2011) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2010.07568.x · Cited by 108 · cited 1×
“, [14, 15] a safety assessment will be performed after 3 cycles of nivolumab monotherapy (6 weeks), during which the investigator will decide if a patient is eligible to receive nivolumab/ipilimumab combination therapy (Nivo 240mg fixed dose Q2W; ipilimumab 1mg/kg Q6W; arm A) or continues nivolumab monotherapy (240 mg…”
BackgroundSmoking, Alcohol Drinking and Esophageal Cancer: Findings from the JACC Study
Sakata, K., Hoshiyama, Y., Morioka, S., Hashimoto, T., Takeshita, T., & Tamakoshi, A. (2005) · Journal of Epidemiology · doi:10.2188/jea.15.s212 · Cited by 70
Okada, E., Ukawa, S., Nakamura, K., Hirata, M., Nagai, A., Matsuda, K., Ninomiya, T., Kiyohara, Y., Muto, K., Kamatani, Y., et al. (2017) · Journal of Epidemiology · doi:10.1016/j.je.2016.12.002 · Cited by 42
Noronha, V., Prabhash, K., Joshi, A., Patil, V., Talole, S. D., Nakti, D., Sahu, A., Shah, S., Laskar, S. G., Patil, P. S., et al. (2016) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504016x14537290676865 · Cited by 32
Multimodal therapy is feasible in elderly anal cancer patients
Dale, J. E., Sebjornsen, S., Leh, S. M., Rösler, C., Aaserud, S., Møller, B., Fluge, Ø., Erichsen, C., Nadipour, S., Kørner, H., et al. (2016) · Acta Oncologica · doi:10.1080/0284186x.2016.1244356 · Cited by 14
Cited by
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
“Some drugs that target the immune checkpoint receptors CTLA-4, 635 PD-1 (nivolumab, 636 pembrolizumab, 637 and cemiplimab, 638 ) and PD-L1 (avelumab, 639 durvalumab, 640 and atezolizumab 641 ) have also been in clinical trials.”
BackgroundDavis, K. L., Fox, E., Isikwei, E., Reid, J. M., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., & Mackall, C. L. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2164 · Cited by 75
Gorbet, M.-J., & Ranjan, A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107456 · Cited by 68
Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review
Zhang, W., Wang, P., & Pang, Q. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4625 · Cited by 64
Zheng, Y., Liu, X., Sun, H., Xu, J., Shen, S., Ba, Y., Yan, M., Qin, Z., Liu, B., Wang, Z., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-5404 · Cited by 39
Metadata
- Authors
- Meindl-Beinker, N. M., Betge, J., Gutting, T., Burgermeister, E., Belle, S., Zhan, T., Schulte, N., Maenz, M., Ebert, M. P., & Haertel, N.
- Affiliations
- Heidelberg University (DE)
- AIO Studien gGmbH (DE)
- ORCID
- Venue
- BMC Cancer
- Published
- 2019-03-14
- Volume
- 19
- Issue
- 1
- Pages
- 231-231
- ISSN
- 1471-2407 (ISSN-L)
- PMC
- PMC6419339
- OpenAlex
- W2936810997
- Cited by
- 30
- References
- 35
- Citations by year
- 2025: 3 · 2024: 6 · 2023: 2 · 2022: 5 · 2021: 4 · 2020: 7 · 2019: 3
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- BMC Cancer (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- heiDOK (Heidelberg University) (acceptedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- sponsored by AIO-Studien gGmbH funded by BMS (AIO-STO-0117)
- grants from the State of Baden-Württemberg for “Center of Geriatric Biology and Oncology (ZOBEL) - Perspektivförderung
- grants from the State of Baden-Württemberg for “Biology of Frailty - Sonderlinie Medizin”
- Medical Faculty Mannheim and the State of Baden-Württemberg
- Deutsche Forschungsgemeinschaft within the funding programme Open Access Publishing, by the Baden-Württemberg Ministry of Science, Research and Arts and by Ruprecht-Karls-Universität Heidelberg
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Keywords
- esophageal squamous cell carcinoma, nivolumab, ipilimumab, immune checkpoint inhibitors, second-line therapy, elderly patients, overall survival, frailty, geriatric assessment, PD-1, PD-L1, predictive biomarkers, microbiome, organoid culture, quality of life
- MeSH terms
- Ipilimumab, Nivolumab, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Esophageal Neoplasms, Humans, Survival Analysis, Treatment Outcome, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.